We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+5.15%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$165M
AUM Growth
-$22.1M
Cap. Flow
-$24.2M
Cap. Flow %
-14.7%
Top 10 Hldgs %
76.79%
Holding
40
New
10
Increased
2
Reduced
11
Closed
15

Top Buys

Rank Stock Value
1
HTGM
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
+$6.12M
2
RIGL icon
Rigel Pharmaceuticals
RIGL
+$5.33M
3
ADMA icon
ADMA Biologics
ADMA
+$4.15M
4
ATXS
Astria Therapeutics
ATXS
+$3.69M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.48M

Top Sells

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$6.43M
2
BSTC
BioSpecifics Technologies Corp.
BSTC
+$5.54M
3
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$5.26M
4
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$4.99M
5
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.78M

Sector Composition

Rank Sector Weight
1 Healthcare 99.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EOLS icon
26
Evolus
EOLS
$377M
– –
-59,229
Closed -$535K
HYPD
27
Hyperion DeFi Inc
HYPD
$41.5M
– –
-499
Closed -$365K
NGNE icon
28
Neurogene
NGNE
$744M
– –
-1,019
Closed -$287K
SCYX icon
29
SCYNEXIS
SCYX
$42.4M
– –
-4,751
Closed -$509K
VCYT icon
30
Veracyte
VCYT
$4.72B
– –
-773,889
Closed -$4.3M
NVTA
31
DELISTED
Invitae Corporation
NVTA
– –
-219,022
Closed -$1.03M
SRRA
32
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-14,275
Closed -$1.18M
ZSAN
33
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-5,714
Closed -$1.01M
OXFD
34
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-263,974
Closed -$3.29M
FOMX
35
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-129,756
Closed -$666K
DOVA
36
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
– –
-184,000
Closed -$4.99M
IVTY
37
DELISTED
Invuity, Inc
IVTY
– –
-507,028
Closed -$1.95M
STDY
38
DELISTED
SteadyMed Ltd
STDY
– –
-721,308
Closed -$2.34M
IMDZ
39
DELISTED
Immune Design Corp.
IMDZ
– –
-161,226
Closed -$532K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Stonepine Capital Management held 40 positions worth $165M, down 12% from $187M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Stonepine Capital Management withdrew a net $24.2M in Q2 2018, closing 15 positions and reducing 11 holdings. Its most notable exit was Dova Pharmaceuticals, Inc. Common Stock, an estimated $4.99M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in HTG Molecular Diagnostics, Inc. Common Stock worth $5.51M.

  • Stonepine Capital Management's largest Q2 2018 buy was HTG Molecular Diagnostics, Inc. Common Stock: 9,384 shares worth $5.51M.
  • Stonepine Capital Management added most to IVERIC bio, Inc. Common Stock in Q2 2018, an estimated $880K increase.
  • Stonepine Capital Management's biggest Q2 2018 reduction was Vanda Pharmaceuticals, cutting an estimated $6.43M.
  • Stonepine Capital Management fully exited Dova Pharmaceuticals, Inc. Common Stock in Q2 2018, selling an estimated $4.99M.
  • Stonepine Capital Management's ten largest holdings make up 77% of its $165M portfolio in Q2 2018.
  • Stonepine Capital Management opened 10 new positions and closed 15 in Q2 2018.
  • Stonepine Capital Management's portfolio value fell 12% quarter-over-quarter to $165M.

Based on Stonepine Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.